切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2020, Vol. 14 ›› Issue (01) : 66 -69. doi: 10.3877/cma.j.issn.1674-3946.2020.01.020

所属专题: 文献

论著

新辅助化疗结合腹腔镜胃癌根治术治疗进展期胃癌的生存质量及生存率分析
李磊1,(), 费建东1, 宋利琴1, 王韬1, 聂双发1, 杜园1, 杨本鑫1   
  1. 1. 075000 河北张家口,河北北方学院附属第一医院胃肠外科
  • 收稿日期:2019-01-23 出版日期:2020-02-26
  • 通信作者: 李磊

Effect of survival quality and survival rate in patients of advanced gastric carcinoma treated with neoadjuvant chemotherapy combined with laparoscopic radical gastrectomy

Lei Li1,(), Jiandong Fei1, Liqin Song1, Tao Wang1, Shuangfa Nie1, Yuan Du1, Benxin Yang1   

  1. 1. Department of Gastrointestinal Surgery, First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000
  • Received:2019-01-23 Published:2020-02-26
  • Corresponding author: Lei Li
  • About author:
    Corresponding author: Li Lei, Email:
  • Supported by:
    Zhangjiakou Science and Technology Project(No.1821055D)
引用本文:

李磊, 费建东, 宋利琴, 王韬, 聂双发, 杜园, 杨本鑫. 新辅助化疗结合腹腔镜胃癌根治术治疗进展期胃癌的生存质量及生存率分析[J/OL]. 中华普外科手术学杂志(电子版), 2020, 14(01): 66-69.

Lei Li, Jiandong Fei, Liqin Song, Tao Wang, Shuangfa Nie, Yuan Du, Benxin Yang. Effect of survival quality and survival rate in patients of advanced gastric carcinoma treated with neoadjuvant chemotherapy combined with laparoscopic radical gastrectomy[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(01): 66-69.

目的

分析新辅助化疗结合腹腔镜胃癌根治术治疗进展期胃癌的生存质量及生存率。

方法

选择2012年8月至2015年8月172例进展期胃癌患者,依据随机对照原则分为对照组(86例)、SOX组(86例)。两组均接受腹腔镜胃癌根治术治疗,SOX组于术前实施肠内营养+新辅助化疗2周期。采用SPSS 25.0软件进行数据处理,围手术期营养指标、生存质量以(±s)表示,采用独立t检验;近期疗效、R0切除率、生存率采用χ2检验,P<0.05为差异有统计学意义。

结果

SOX组治疗总有效率(58.1%)、疾病控制率(89.5%)及R0切除率(70.9%)均比对照组高(43.0%、75.6%、55.8%),P<0.05;术后7 d两组血清白蛋白、前白蛋白、血红蛋白水平比术前降低,但SOX组上述指标均比对照组高(P<0.05);术后1年SOX组健康状况调查简表(SF-36)评分均比对照组高,3年总生存率(77.9%)及术后第3年无病生存率(74.4%)均比对照组(60.5%、59.3%)高(P<0.05)。

结论

新辅助化疗结合腹腔镜胃癌根治术治疗进展期胃癌疗效确切,可提高肿瘤切除率及生存率,改善生存质量;化疗期间接受规范化肠内营养可改善营养状况。

Objective

To analyze the quality of life and survival rate of patients with advanced gastric cancer treated by neoadjuvant chemotherapy combined with laparoscopic radical gastrectomy

Methods

172 patients with advanced gastric carcinoma treated in the hospital from August 2012 to August 2015 were retrospectively analyzed, and they were divided into control group (86 cases) and SOX group (86 cases) according to the randomized controlled method. Both the two groups received laparoscopic radical gastrectomy, and two cycles of enteral nutrition and neoadjuvant chemotherapy before surgery were given in the SOX groups. The data were processed by SPSS 25 software. Perioperative nutritional index, quality of life as (±s) were compared using the independent t test. The short-term curative effect, R0 resection rate and survival rate were compared by χ2 test, P<0.05 was statistically significant.

Results

The total effective rate, disease control rate and R0 resection rate in SOX group (58.1%, 89.5%, 70.9%) were higher than those in control group (43.0%, 75.6%, 55.8%) (P<0.05); The levels of postoperative 7 d serum albumin (Alb), prealbumin (PA), hemoglobin (Hb) in the two groups were lower than those before surgery, and the above indexes in SOX group were higher than those in control group (P<0.05); The score of MOS item short from health survey (SF-36) in SOX group was higher than that in control group, the three-year overall survival rate and postoperative third-year disease-free survival rate in SOX group (77.9%, 74.4%) were higher than those in control group (60.5%, 59.3%) (P<0.05).

Conclusion

Neoadjuvant chemotherapy combined with laparoscopic radical resection of gastric cancer in treatment of advanced gastric cancer is effective, which can improve the resection rate and survival rate, improve the quality of life; chemotherapy received standard enteral nutrition can improve the nutritional status.

表1 172例进展期胃癌患者不同疗法两组一般资料对比[(±s),例]
表2 172例进展期胃癌患者不同疗法两组近期疗效及R0切除率对比[例(%)]
图1 172例进展期胃癌患者不同疗法两组围术期营养指标对比
表3 172例进展期胃癌患者不同疗法两组SF-36评分对比[(±s),分]
表4 172例进展期胃癌患者不同疗法两组术后生存率对比[例(%)]
[1]
季加孚,王宇宸,肖琪严.中国胃癌腹腔镜手术临床研究现状[J/CD].中华普外科手术学杂志(电子版),2019,13(2):109-113.
[2]
温志华,王旺河,郭艳丽,等.腹腔镜辅助D2根治性全胃切除术与传统开腹手术治疗胃癌的近期疗效及血清学变化比较[J].癌症进展,2017,15(5):528-530,550.
[3]
姜培娣,岳健,王雪,等.多西他赛联合奥沙利铂及卡培他滨在晚期胃癌姑息化疗中的疗效[J/CD].中华普外科手术学杂志(电子版),2019,13(2):131-133.
[4]
Huang XE, Wang L, Ji ZQ,et al.Safety of Lienal Polypeptide Injection Combined with Chemotherapy in Treating Patients with Advanced Cancer[J].Asian Pac J Cancer Prev,2015,16(17):7837-7841.
[5]
中华人民共和国国家卫生和计划生育委员会.胃癌规范化诊疗指南(试行)[J/CD].中国医学前沿杂志(电子版),2013,5(8):56-63.
[6]
中华医学会外科学分会腹腔镜与内镜外科学组.腹腔镜胃癌手术操作指南(2007版)[J].中华消化外科杂志,2007,6(6):476-480.
[7]
Brown DR, Lanciano R, Heal C,et al.The effect of whole-brain radiation (WBI) and Karnofsky performance status (KPS) on survival of patients receiving stereotactic radiosurgery (SRS) for second brain metastatic event[J].J Radiat Oncolo,2017,6(1):31-37.
[8]
Jang ES, Kim YS, Kim KA,et al.Factors Associated with Health-Related Quality of Life in Korean Patients with Chronic Hepatitis C Infection Using the SF-36 and EQ-5D[J].Gut Liver,2018,12(4):440-448.
[9]
黄景山,苏昭然,王贵和.腹腔镜辅助D2根治术与开腹手术治疗进展期胃癌的疗效对比研究[J].安徽医学,2017,38(6):709-712.
[10]
孙涛,左富义,崔伟.使用奥沙利铂联合替吉奥对进展期胃癌进行新辅助化疗的效果及安全性评价[J/CD].中华普外科手术学杂志(电子版),2017,11(3):202-205.
[11]
闫晓红,赵亚宁,汪华,等.阿帕替尼联合奥沙利铂+替吉奥治疗晚期胃癌效果观察[J].肿瘤研究与临床,2017,29(11):761-764.
[12]
王红兵,雷霄.XELOX方案与SOX方案在胃癌新辅助治疗中的应用价值[J].实用癌症杂志,2017,32(6):989-991.
[13]
Tan B, Li Y, Di Y,et al.Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer[J]. J Clin Lab Anal,2017,32(4):e22363.
[14]
徐凯,崔明,邢加迪,等.腹腔镜辅助胃癌根治术对老年胃癌患者的临床疗效分析[J].中国肿瘤临床,2017,44(16):800-804.
[15]
张智,沈健,庾庆丽.雷替曲塞联合奥沙利铂二线治疗晚期胃癌的疗效及安全性[J].现代肿瘤医学,2018,26(1):80-84.
[16]
贺华,周美红,张勇.贝伐单抗与卡培他滨联合奥沙利铂方案对老年晚期胃癌术后血清肿瘤标志物及生活质量的影响[J].中国药业,2017,26(5):69-72.
[17]
王海英,汤虹,周孟强,等.SOX化疗方案联合复方斑蝥胶囊治疗老年晚期胃癌的效果[J].中国老年学杂志,2018,38(1):142-144.
[18]
Liu X, Li G, Long Z,et al.Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer[J].J Surg Oncol,2018,117(4):692-698.
[19]
张迪,张立,陆宏伟,等.肠内营养支持对进展期胃癌术后营养及化疗耐受性的影响[J].中国现代医学杂志,2018,28(28):122-126.
[1] 燕速, 霍博文. 腹腔镜食管胃结合部腺癌根治性切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 13-13.
[2] 母德安, 李凯, 张志远, 张伟. 超微创器械辅助单孔腹腔镜下脾部分切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 14-14.
[3] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[4] 李子禹, 卢信星, 李双喜, 陕飞. 食管胃结合部腺癌腹腔镜手术重建方式的选择[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 5-8.
[5] 李乐平, 张荣华, 商亮. 腹腔镜食管胃结合部腺癌根治淋巴结清扫策略[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 9-12.
[6] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[7] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[8] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[9] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[10] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[11] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[12] 李博, 贾蓬勃, 李栋, 李小庆. ERCP与LCBDE治疗胆总管结石继发急性重症胆管炎的效果[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 60-63.
[13] 王庆亮, 党兮, 师凯, 刘波. 腹腔镜联合胆道子镜经胆囊管胆总管探查取石术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 313-313.
[14] 杨建辉, 段文斌, 马忠志, 卿宇豪. 腹腔镜下脾部分切除术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 314-314.
[15] 叶劲松, 刘驳强, 柳胜君, 吴浩然. 腹腔镜肝Ⅶ+Ⅷ段背侧段切除[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 315-315.
阅读次数
全文


摘要